NASDAQ:SCPH - Scpharmaceuticals Stock Price, News & Analysis

+0.11 (+1.77 %)
(As of 08/21/2019 07:53 AM ET)
Today's Range
Now: $6.31
50-Day Range
MA: $5.00
52-Week Range
Now: $6.31
Volume56,227 shs
Average Volume63,915 shs
Market Capitalization$117.24 million
P/E RatioN/A
Dividend YieldN/A
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SCPH



Sales & Book Value

Annual SalesN/A
Book Value$4.24 per share


Net Income$-29,440,000.00


Market Cap$117.24 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive SCPH News and Ratings via Email

Sign-up to receive the latest news and ratings for SCPH and its competitors with MarketBeat's FREE daily newsletter.

Scpharmaceuticals (NASDAQ:SCPH) Frequently Asked Questions

What is Scpharmaceuticals' stock symbol?

Scpharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."

How were Scpharmaceuticals' earnings last quarter?

Scpharmaceuticals Inc (NASDAQ:SCPH) issued its earnings results on Wednesday, August, 7th. The company reported ($0.39) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.49) by $0.10. View Scpharmaceuticals' Earnings History.

When is Scpharmaceuticals' next earnings date?

Scpharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Scpharmaceuticals.

What price target have analysts set for SCPH?

2 equities research analysts have issued 1-year price targets for Scpharmaceuticals' stock. Their predictions range from $5.00 to $5.00. On average, they expect Scpharmaceuticals' stock price to reach $5.00 in the next twelve months. This suggests that the stock has a possible downside of 20.8%. View Analyst Price Targets for Scpharmaceuticals.

What is the consensus analysts' recommendation for Scpharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scpharmaceuticals in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Scpharmaceuticals.

Has Scpharmaceuticals been receiving favorable news coverage?

Media stories about SCPH stock have trended positive recently, InfoTrie reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Scpharmaceuticals earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the next several days. View News Stories for Scpharmaceuticals.

Are investors shorting Scpharmaceuticals?

Scpharmaceuticals saw a decline in short interest in the month of July. As of July 31st, there was short interest totalling 103,400 shares, a decline of 28.8% from the June 30th total of 145,200 shares. Based on an average daily volume of 78,200 shares, the short-interest ratio is presently 1.3 days. Currently, 1.2% of the shares of the company are short sold. View Scpharmaceuticals' Current Options Chain.

Who are some of Scpharmaceuticals' key competitors?

What other stocks do shareholders of Scpharmaceuticals own?

Who are Scpharmaceuticals' key executives?

Scpharmaceuticals' management team includes the folowing people:
  • Mr. John H. Tucker, Pres, CEO, CFO & Director (Age 56)
  • Dr. Pieter Muntendam, Consultant (Age 61)
  • Ms. Rachael Nokes, Principal Accounting Officer
  • Katherine Taudvin, Director of Corp. Devel. & Investor Relations
  • Dr. John Mohr Pharm.D., Sr. VP of Clinical Devel. & Medical Affairs

When did Scpharmaceuticals IPO?

(SCPH) raised $96 million in an initial public offering on Friday, November 17th 2017. The company issued 6,400,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Who are Scpharmaceuticals' major shareholders?

Scpharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Eversept Partners LP (0.94%), Vanguard Group Inc. (0.48%), Northern Trust Corp (0.36%), Alambic Investment Management L.P. (0.32%), Jacobs Levy Equity Management Inc. (0.20%) and Paloma Partners Management Co (0.16%). Company insiders that own Scpharmaceuticals stock include 5Am Partners Iv, Llc and Ra Capital Healthcare Fund Lp. View Institutional Ownership Trends for Scpharmaceuticals.

Which institutional investors are selling Scpharmaceuticals stock?

SCPH stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Parametric Portfolio Associates LLC, SG Americas Securities LLC and Northern Trust Corp. View Insider Buying and Selling for Scpharmaceuticals.

Which institutional investors are buying Scpharmaceuticals stock?

SCPH stock was bought by a variety of institutional investors in the last quarter, including Eversept Partners LP, Alambic Investment Management L.P., Paloma Partners Management Co, Jacobs Levy Equity Management Inc. and Morgan Stanley. Company insiders that have bought Scpharmaceuticals stock in the last two years include 5Am Partners Iv, Llc and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for Scpharmaceuticals.

How do I buy shares of Scpharmaceuticals?

Shares of SCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Scpharmaceuticals' stock price today?

One share of SCPH stock can currently be purchased for approximately $6.31.

How big of a company is Scpharmaceuticals?

Scpharmaceuticals has a market capitalization of $117.24 million. The company earns $-29,440,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Scpharmaceuticals employs 21 workers across the globe.View Additional Information About Scpharmaceuticals.

What is Scpharmaceuticals' official website?

The official website for Scpharmaceuticals is

How can I contact Scpharmaceuticals?

Scpharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company can be reached via phone at 617-517-0730 or via email at [email protected]

MarketBeat Community Rating for Scpharmaceuticals (NASDAQ SCPH)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  112 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  219
MarketBeat's community ratings are surveys of what our community members think about Scpharmaceuticals and other stocks. Vote "Outperform" if you believe SCPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/21/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel